Kanaph Therapeutics Inc.
0082N0
企业摘要
季度业绩走势
营业收入
营业利润率
市场偏好度
※ 点击图表可查看该月份的AI分析信息。
营业收入
合并
单独
营业利润
合并
单独
净利润
合并
单独
财务信息
保存为Excel
该期间没有财务信息数据。
~
季度
决算
*单位基准小数点第四位以下的数值标记为'0/-0'
财务指标预测
※ 本预测值是基于历史数据的AI简单估算值，可能与实际业绩存在差异。
企业概况
截至2026年6月
Kanaph Therapeutics Inc. is an innovative new drug development company that develops anti-cancer agents and treatments for ophthalmic diseases based on human genome-based drug development technology. The company's core technology lies in discovering novel targets with high unmet medical needs through the analysis of human genome data and disease-specific biological signatures, and developing innovative new drugs of various modalities, including bispecific antibodies, antibody-drug conjugates (ADC), and synthetic new drugs, based on these targets; the core of new drug development lies in selecting the appropriate target for each disease and securing both efficacy and safety simultaneously through drug design optimized for that target.
代表理事
Lee Byeongcheol
成立日期
2019年2月14日
法人类型
韩国创业板
行业分类
Research and experimental development on medical sciences and pharmacy
法人注册号
11011-7013206
营业执照号
643-87-01092
电话号码
02-798-9438
传真号码
02-792-8638
公司地址
3 Itaewon-ro 55ga-gil, Yongsan-gu, Seoul
评论